Sophiris Bio Inc. (SPHS)

Oncology Corporate Profile

Stock Performance

2.8400
0.0000

HQ Location

1258 Prospect Street
La Jolla, CA 92037

Company Description

Sophiris Bio Inc. is a biopharmaceutical company developing PRX302, a clinical-stage, targeted therapy for the treatment of urological diseases. PRX302 is in Phase 3 clinical development for the treatment of the symptoms of benign prostatic hyperplasia (BPH) and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. PRX302 is also currently in a Phase 2a proof of concept study for the treatment of localized low to intermediate risk prostate cancer.

Website: http://www.sophirisbio.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
topsalysin / PRX302prostate-specific antigen (PSA) inhibitorProstate cancerII

View additional information on product candidates here »

Source


http://www.sophirisbio.com/

Recent News Headlines

Sophiris Bio Reports Fourth Quarter and Full Year 2016 Financial Results and Key Corporate Highlights

3/27/2017 01:00 pm

[PR Newswire] - SAN DIEGO and VANCOUVER, British Columbia, March 27, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company ...

Topsalysin Data from Successful Phase 2a Localized Prostate Cancer Study to be Presented at the 32nd European Association of Urology Congress

3/23/2017 08:00 pm

[PR Newswire] - SAN DIEGO and VANCOUVER, British Columbia, March 23, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company ...

Sophiris Bio to Present at 29th Annual ROTH Conference

3/6/2017 09:00 pm

[PR Newswire] - SAN DIEGO and VANCOUVER, British Columbia, March 6, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 29th Annual ROTH Conference. The presentation is scheduled for Monday, March 13, 2017 at 5:00 p.m. PDT at The Ritz-Carlton, Dana Point, California. The presentation will be webcast live and can be accessed through the Investor Relations page at www.sophiris.com.

Sophiris Bio to Webcast Live Presentation at BetterInvesting's Virtual Investor Conference

1/30/2017 09:00 pm

[CNW Group] - Sophiris Bio to Webcast Live Presentation at BetterInvesting's Virtual Investor Conference

Sophiris Bio to Webcast Live Presentation at BetterInvesting's Virtual Investor Conference

1/30/2017 09:00 pm

[PR Newswire] - SAN DIEGO and VANCOUVER, British Columbia, Jan. 30, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the BetterInvesting™ Virtual Investor Conference. The presentation will take place on Thursday February 2, 2017 at 1:00 p.m. Eastern Time. The presentation will be webcast live at http://tinyurl.com/0202prepr and can also be accessed through the Investor Relations page at www.sophiris.com.

Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present February 2nd

1/30/2017 07:01 pm

[CNW Group] - Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present February 2nd

Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present February 2nd

1/30/2017 07:01 pm

[PR Newswire] - CEOs & CFOs share vision, answer questions live at VirtualInvestorsConferences.com NEW YORK, Jan. 30, 2017 /PRNewswire/ -- PR Newswire and BetterInvesting (NAIC) today announced the agenda for the ...

Sophiris Bio to Present at 28th Annual Piper Jaffray Healthcare Conference

11/22/2016 01:00 pm

[PR Newswire] - SAN DIEGO and VANCOUVER, British Columbia, Nov. 22, 2016 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin ...

Sophiris Bio reports 3Q loss

11/9/2016 09:01 pm

Sophiris Bio reports 3Q loss

11/9/2016 09:01 pm

Sophiris Bio Reports Third Quarter 2016 Financial Results and Key Business Highlights

11/9/2016 09:01 pm

[at noodls] - SAN DIEGO and VANCOUVER, British Columbia, Nov. 9, 2016 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the 'Company' or 'Sophiris'), a biopharmaceutical company developing topsalysin (PRX302) for the ...

Sophiris Bio Reports Third Quarter 2016 Financial Results and Key Business Highlights

11/9/2016 09:00 pm

[PR Newswire] - SAN DIEGO and VANCOUVER, British Columbia, Nov. 9, 2016 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin ...

Sophiris Bio to Present at the 2016 BIO Investor Forum

10/10/2016 08:00 pm

[PR Newswire] - SAN DIEGO and VANCOUVER, British Columbia, Oct. 10, 2016 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin ...

Sophiris Bio Closes Underwritten Public Offering

8/26/2016 08:01 pm

[at noodls] - SAN DIEGO and VANCOUVER, British Columbia, Aug. 26 2016 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the 'Company'), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of ...

Sophiris Bio Closes Underwritten Public Offering

8/26/2016 08:00 pm

[PR Newswire] - With the proceeds from the offering, the Company plans to conduct a second Phase 2 clinical trial of topsalysin for the treatment of localized prostate cancer. The Company expects that this clinical trial will enroll approximately 40 patients at two or more trial sites and the Company is exploring potential trial sites in the United States.